Erste Asset Management’s AbCellera Biologics ABCL Stock Holding History

Erste Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$503K	Hold	62,000	–	–	﹤0.01%	515
2026 Q1	$203K	Hold	62,000	–	–	﹤0.01%	564
2025 Q4	$215K	Hold	62,000	–	–	﹤0.01%	545
2025 Q3	$302K	Hold	62,000	–	–	﹤0.01%	532
2025 Q2	$224K	Hold	62,000	–	–	﹤0.01%	746
2025 Q1	$143K	Hold	62,000	–	–	﹤0.01%	484
2024 Q4	$185K	Hold	62,000	–	–	﹤0.01%	487
2024 Q3	$162K	Hold	62,000	–	–	﹤0.01%	487
2024 Q2	$179K	Hold	62,000	–	–	﹤0.01%	481
2024 Q1	$278K	Hold	62,000	–	–	﹤0.01%	467
2023 Q4	$368K	Hold	62,000	–	–	0.01%	449
2023 Q3	$289K	Hold	62,000	–	–	0.01%	455
2023 Q2	$408K	Hold	62,000	–	–	0.01%	437
2023 Q1	$460K	Hold	62,000	–	–	0.01%	428
2022 Q4	$623K	Hold	62,000	–	–	0.01%	408
2022 Q3	$611K	Hold	62,000	–	–	0.01%	397
2022 Q2	$627K	Hold	62,000	–	–	0.01%	406
2022 Q1	$605K	Buy	+62,000	New	+$587K	0.01%	420

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Erste Asset Management's ABCL Position: Q2 2026 in Review

Erste Asset Management held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 62,000 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #515.

Erste Asset Management first reported a position in ABCL in Q1 2022 and has held it in 18 quarters since. The position peaked at $627K in Q2 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Erste Asset Management held 62,000 shares of AbCellera Biologics worth $503K as of Q2 2026.
Erste Asset Management left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up ﹤0.01% of Erste Asset Management's portfolio in Q2 2026, its #515 holding.
Erste Asset Management first reported a position in AbCellera Biologics in Q1 2022 and has held it in 18 quarters since.
Erste Asset Management's AbCellera Biologics position peaked at $627K in Q2 2022.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.